<DOC>
	<DOCNO>NCT03095456</DOCNO>
	<brief_summary>This study randomize , double-blind , double-dummy , parallel group study compare daily nebulized Revefenacin Spiriva daily deliver via HandiHalerÂ® lung function subject COPD Low Peak Inspiratory Flow Rate .</brief_summary>
	<brief_title>Revefenacin Peak Inspiratory Flow Rate ( PIFR ) Study COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Subject male female subject 40 year age old diagnosis COPD . Subject current past cigarette smoke history ( equivalent cigar pipe smoke history ) least 10 packyears . Subject willing able provide sign dated write informed consent participate prior initiation study related procedure . Subject concurrent disease condition , opinion investigator , would interfere continue study participation confound evaluation safety tolerability study drug . Subject history reaction hypersensitivity inhale nebulized anticholinergic . Subject suffers medical condition would preclude use inhaled anticholinergic , include narrowangle glaucoma , symptomatic benign prostatic hyperplasia , bladder neck obstruction , urinary retention .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease , COPD , Low Peak Inspiratory Flow Rate</keyword>
</DOC>